|
業務類別
|
Biotechnology |
|
業務概覽
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
| 公司地址
| 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134 |
| 電話號碼
| +1 857 529-8300 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.x4pharma.com |
| 員工數量
| 143 |
| Mr. Adam Raymond Craig, M.D. |
Executive Chairman of the Board and Principal Executive Officer |
-- |
12/08/2025 |
| Mr. John Volpone |
President and Chief Operating Officer |
-- |
17/09/2025 |
| Mr. Christophe Arbet-Engels |
Chief Medical Officer |
-- |
25/04/2025 |
|
|
| Mr. Michael Stephen Wyzga |
Lead Independent Director |
12/08/2025 |
| Dr. Gary J. Bridger, PhD |
Independent Director |
25/04/2025 |
| Mr. Adam Raymond Craig, M.D. |
Executive Chairman of the Board and Principal Executive Officer |
12/08/2025 |
| Dr. Murray W. Stewart, M.D. |
Independent Director |
25/04/2025 |
| Ms. Francoise de Craecker |
Independent Director |
25/04/2025 |
|
|
|
|
